TY  - JOUR
A1  - Hrgovic, Igor
A1  - Kleemann, Johannes
A1  - Doll, Monika
A1  - Loquai, Carmen
A1  - Weid, Florian Jürgen
A1  - Louwen, Frank
A1  - Zöller, Nadja Nicole
A1  - Kippenberger, Stefan
A1  - Kaufmann, Roland
A1  - Meissner, Markus
T1  - Evaluation of 2‑methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma
T2  - Molecular and clinical oncology
N2  - Experimental findings indicated that 2‑methoxyestradiol (2‑ME), an endogenous metabolite of 17β‑estradiol, may exhibit anti‑tumorigenic properties in various types of tumour, such as melanoma and endometrial carcinoma. In patients with endometrial cancer, the serum levels of 2‑ME are decreased compared with those in healthy controls, and this finding has been associated with a poor outcome. The aim of the present study was to examine whether the serum levels of 2‑ME are decreased in patients with melanoma, and whether this decrease may be correlated with disease stage and, therefore, serve as a prognostic indicator. ELISA was used to detect serum levels of 2‑ME in patients with stage I‑IV malignant melanoma (MM). A cohort of 78 patients with MM was analysed, along with 25 healthy controls, among whom 15 were women in the second trimester of pregnancy (positive control). As expected, significantly elevated levels of serum 2‑ME were observed in pregnant control patients compared with those in patients with MM and healthy controls. There was no observed correlation between 2‑ME serum levels in patients with MM and disease stage, tumour thickness, lactate dehydrogenase or S100 calcium‑binding protein B levels. In addition, the 2‑ME levels of patients with MM did not differ significantly from those of normal healthy controls. Overall, the findings of the present study indicated that the 2‑ME serum levels in patients with MM were not decreased, and there was no correlation with early‑ or advanced‑stage disease. Therefore, in contrast to published results on endometrial cancer, endogenous serum 2‑ME levels in MM were not found to be correlated with tumour stage and did not appear to be a suitable prognostic factor in MM.
KW  - 2‑methoxyestradiol
KW  - melanoma
KW  - lactate dehydrogenase
KW  - stage
KW  - S100 calcium‑binding protein B
KW  - prognostic factor
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62817
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-628170
SN  - 2049-9469
N1  - The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
VL  - 15
IS  - 1, art. 141
SP  - 1
EP  - 5
PB  - Spandidos Publ.
CY  - Athens
ER  -